



WARNING LETTER
2003-DT-18

Food and Drug Administration
Detroit District
300 River Place
Suite 5900
Detroit, MI 48207
Telephone: 313-393-8100
FAX: 313-393-8139

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

July 29, 2003

Ms. Julie Dalrymple
Center Administrator
C.H.S. Radiology of Marion
1391 North Baldwin Ave.
Marion, IN 46940

Dear Ms. Dalrymple:

We are writing you because on July 2, 2003, your facility was inspected by a representative of the State of Indiana acting on behalf of the Food & Drug Administration (FDA). The inspection revealed a serious deficiency in the quality of the mammography services offered by your facility.

Under the Mammography Quality Standards Act of 1992 (MQSA), 42 U.S.C. § 263b, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography.

The recent inspection at your facility revealed the following Level 1 finding:

1. During the month of June, 2003, processor quality control (QC) records were missing for at least 30% of the days when mammograms were processed including 5 consecutive days with missing processor QC records. This is in violation of Title 21, Code of Federal Regulations (C.F.R.), Section 900.12 (d)(2): see 21 C.F.R. § 900.12 (e)(1).

The specific violation noted above appeared on your MQSA Facility Inspection Report (copy enclosed), which your facility received at the close of the inspection. This problem is identified as a Level 1 because it identifies a failure to meet a significant MQSA requirement.

This condition may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, and it represents a violation of the law that may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan

Page 2

of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against performing further mammography.

In addition, you should also address the following Level 2 finding that was listed on the inspection report provided to you at the close of the inspection.

1. During the month of June, 2003, phantom QC records were missing for at least 2 of the 4 weeks. This is in violation of Title 21 C.F.R. § 900.12 (d)(2): see 21 C.F.R. § 900.12 (e)(2).

It is necessary for you to act on this matter immediately. Please provide to this office in writing within fifteen (15) working days from the date you receive this letter:

- the specific steps you have taken to correct the Level 1 and 2 violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- the sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records. (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to: Mr. David M. Kaszubski
Director Compliance Branch
U. S. Food & Drug Administration
300 River Place, Suite 5900
Detroit, MI 48207


Please note that FDA regulations do not preclude a State from enforcing its own State mammography laws and regulations. In some cases, these requirements may be more stringent than FDA's. When you plan your corrective actions, you should consider the more stringent State requirements, if any. You should also send a copy of your response to the State of Indiana radiation control office that conducted the inspection referenced in this letter. You may choose to address both the FDA and any additional State requirements in your response.

There are many FDA requirements pertaining to mammography. This letter only concerns the findings of your recent inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography>.

Page 3

If you have any questions regarding this letter or how to ensure that you are meeting MQSA standards, please call Mr. Dennis E. Swartz, Radiological Health Specialist, at 313-393-8156.

Sincerely yours,



Joann M. Givens
District Director
Detroit District Office

Enclosure (MQSA Facility Inspection Report)